Dual Chamber Pacemakers

Dual Chamber Pacemakers

Double-chamber pacemakers are specialized cardiac devices employing leads inserted into both the atrium and ventricle of the heart. They work by coordinating electrical signals between these chambers, aiding in the regulation of heart rhythm and enhancing its effectiveness. By synchronizing atrial and ventricular functions, these devices aim to replicate the natural rhythm of the heart, providing support when the heart's electrical system requires assistance. Several other factors, such as rising genetic disorders and unhealthy lifestyles are leading drivers of dual-chamber pacemakers globally. For instance, according to the BMC Public Health, in July 2023, the prevalence of unhealthy lifestyles was 86.4% for diet, 14.5% for alcohol, 6.0% for tobacco, 72.2% for physical activity, 42.3% for screen time, and 63.9% for sleep duration.

The Dual Chamber Pacemakers Market is expected to grow at a steady rate of around 4.5% owing to the increased prevalence of alcohol and tobacco globally. According to the 2021 National Survey on Drug Use and Health (NSDUH), 29.5 million people ages 12 and older had Alcohol Use Disorder (AUD) in the year 2020. Several factors, including a surge in the incidence of cardiac disorders, increasing awareness regarding throat cancer, increasing smoking population, rising alcoholism culture, and increased investments in cardiology departments are driving the growth of the market during the forecast period. Apart from this, accelerated treatment efficiency with dual-chamber pacemakers has resulted in faster treatment procedures and better accuracy which is also driving this market of dual-chamber pacemakers at a steady rate.

• Based on product type, the market is segmented into implantable pacemakers and external pacemakers. The implantable pacemakers segment held the maximum share in the global market of dual-chamber pacemakers in 2022 owing to the rising number of pacemaker implants performed. For instance, according to the Spanish Society of Cardiology in 2021, there was a 12.8% increase in pacemaker implants compared with 2020 and a 3% increase compared with the average for 2018 to 2019. Implantable pacemakers are surgically implanted into the chest or abdomen, directly connected to the heart, and continuously monitor and regulate the heart's rhythm. They are designed for long-term use and offer ongoing support. This segment dominated the market because of the rising cases of obesity, increasing geriatric population, and increased prevalence of ill lifestyles including smoking, alcoholism, and unhealthy lifestyles among people. A family history of heart disease is also a propelling factor for this segment. Thus, amongst cancer types, the implantable pacemakers segment held a significant share of the market in 2022.
• Based on application, the market is categorized into arrhythmias, bradycardia, and others. The bradycardia segment is expected to hold a significant share of the market in the forecast period owing to the prevalent sedentary lifestyle of people. Bradycardia can be a type of arrhythmia, but not all arrhythmias involve a slow heart rate. Some arrhythmias can cause the heart to beat too fast or irregularly without necessarily slowing it down. This segment is propelled by rising technological advancements. For instance, the incidence of bradycardia was reported to be approximately 1 in 600 individuals worldwide in September 2020 according to the American Journal of Cardiology. Thus, amongst technology, the bradycardia category is expected to witness a higher CAGR during the forecast period.
• For a better understanding of the market adoption of dual chamber pacemakers, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is dominating the market in the current scenario of 2022 due to the increasing smoke pollution, increasing alcohol consumption, and rising number of investments in developing effective dual chamber pacemakers. For example, according to the National Center for Drug Abuse Statistics, in a Johns Hopkins-University of Maryland-Baltimore survey, 60.1% of participants reported drinking more alcohol after March 1, 2020. Government organizations are initiating cardiac disorder awareness programs to provide efficient care to patients. Thus, amongst regions, North America held a significant share of the market in 2022.
• Some of the major players operating in the market include Abbott; Biotronik; Boston Scientific Corporation; Lepu Medical Application (Beijing)Co., Ltd.; LivaNova PLC; MEDICO S.R.L.; Medtronic; Oscor Inc.; OSYPKA MEDICAL; MicroPort Scientific Corporation.